ID   SUP-B28
AC   CVCL_A316
AS   CVCL_DI26
SY   AT-2; AT2
DR   ArrayExpress; E-MTAB-11038
DR   ArrayExpress; E-MTAB-11039
DR   cancercelllines; CVCL_A316
DR   Wikidata; Q54750826
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8231254;
RX   PubMed=8704231;
RX   PubMed=12127395;
RX   PubMed=34940123;
CC   Population: Caucasian and Pacific; Polynesian.
CC   Doubling time: ~3 days (PubMed=12127395).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=34940123).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=34940123).
CC   Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1; Note=ETV6 exon 5/RUNX1 exon 4 and RUNX1 exon 3/ETV6 exon 6 fusions (PubMed=8704231; PubMed=12127395; PubMed=34940123).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous; Note=In 50% of the reads (PubMed=34940123).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous; Note=In 3% of the reads (PubMed=34940123).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: STR profile from personal communication of Ryan R.J.H.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 10
ST   D16S539: 9,12
ST   D18S51: 12,13
ST   D19S433: 13,14
ST   D21S11: 29,33.2
ST   D2S1338: 19,24
ST   D3S1358: 16,18
ST   D5S818: 10,12
ST   D7S820: 10
ST   D8S1179: 12,14
ST   FGA: 20,24
ST   TH01: 9,9.3
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   NCIt; C80334; B lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1) ETV6-RUNX1
DI   ORDO; Orphanet_585929; B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A314 ! SUP-B26
SX   Male
AG   6Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 19
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=8231254;
RA   Zhang L.Q., Downie P.A., Goodell W.R., McCabe N.R., Le Beau M.M.,
RA   Morgan R., Sklar J., Raimondi S.C., Miley D., Goldberg A., Lu M.-M.,
RA   Montag A., Smith S.D.;
RT   "Establishment of cell lines from B-cell precursor acute lymphoblastic
RT   leukemia.";
RL   Leukemia 7:1865-1874(1993).
//
RX   PubMed=8704231; DOI=10.1182/blood.V88.3.785.785;
RA   Kim D.-H., Moldwin R.L., Vignon C., Bohlander S.K., Suto Y.,
RA   Giordano L., Gupta R., Fears S., Nucifora G., Rowley J.D., Smith S.D.;
RT   "TEL-AML1 translocations with TEL and CDKN2 inactivation in acute
RT   lymphoblastic leukemia cell lines.";
RL   Blood 88:785-794(1996).
//
RX   PubMed=12127395; DOI=10.1016/S0165-4608(01)00655-0;
RA   Fears S., Chakrabarti S.R., Nucifora G., Rowley J.D.;
RT   "Differential expression of TCL1 during pre-B-cell acute lymphoblastic
RT   leukemia progression.";
RL   Cancer Genet. Cytogenet. 135:110-119(2002).
//
RX   PubMed=34940123; DOI=10.3390/cimb43030149;
RA   Quentmeier H., Pommerenke C., Drexler H.G.;
RT   "Molecular genetics of pre-B acute lymphoblastic leukemia sister cell
RT   lines during disease progression.";
RL   Curr. Issues Mol. Biol. 43:2147-2156(2021).
//